{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:50:00Z","timestamp":1793731800118,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019573","name":"Amsterdam University Medical Centres","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.euo.2025.04.002","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T23:30:17Z","timestamp":1745623817000},"page":"1286-1294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oncological Outcomes in Patients with Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography\u2013detected Oligometastatic Prostate Cancer Treated with Metastasis-directed Radiotherapy as the Single Treatment Modality"],"prefix":"10.1016","volume":"8","author":[{"given":"Katelijne C.C.","family":"de Bie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte G.","family":"Zuur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennie","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Meijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel A.","family":"Hinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6_suppl","key":"10.1016\/j.euo.2025.04.002_b0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.002_b0010","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen\u2010deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.04.002_b0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.002_b0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.002_b0025","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.04.002_b0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.euf.2020.09.020","article-title":"Prostate-specific membrane antigen positron emission tomography\u2013guided radiotherapy","volume":"7","author":"Kishan","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.04.002_b0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00259-017-3858-2","article-title":"(68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy\u2014diagnostic performance and impact on therapeutic decision-making","volume":"45","author":"Grubm\u00fcller","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2025.04.002_b0040","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.3390\/cancers14143302","article-title":"Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer","volume":"14","author":"Galgano","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2025.04.002_b0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.002_b0050","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.3390\/cancers12113280","article-title":"Recent scientific developments in metastatic prostate cancer","volume":"12","author":"Heidegger","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2025.04.002_b0055","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.euo.2018.09.005","article-title":"Novel insights into the management of oligometastatic prostate cancer: a comprehensive review","volume":"2","author":"Battaglia","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.002_b0060","unstructured":"Nanda S. STOMP 5-year results confirm potential of metastasis-directed therapy in prostate cancer. 2020. https:\/\/oncology.medicinematters.com\/asco-gu-2020\/prostate-cancer\/stomp-5-year-results-metastasis-directed-therapy\/17706826."},{"key":"10.1016\/j.euo.2025.04.002_b0065","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2025.04.002_b0070","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.euo.2025.04.002_b0075","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/1754-9485.12747","article-title":"Use of stereotaxic body radiation therapy for oligometastatic recurrent prostate cancer: a systematic review","volume":"62","author":"Vilela","year":"2018","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.euo.2025.04.002_b0080","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2018.04.017","article-title":"Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography","volume":"1","author":"Kneebone","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.002_b0085","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2021.02.031","article-title":"Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis","volume":"80","author":"Glicksman","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.002_b0090","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.eururo.2014.09.004","article-title":"Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature","volume":"67","author":"Ost","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.002_b0095","doi-asserted-by":"crossref","unstructured":"Ravi P, Zhong C, Xie W, et al. Combined fixed-duration systemic treatment and metastasis-directed radiotherapy for oligometastatic hormone-sensitive prostate cancer. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.10.014.","DOI":"10.1016\/j.euo.2024.10.014"},{"key":"10.1016\/j.euo.2025.04.002_b0100","article-title":"Prostate-specific membrane antigen PET response associates with metastasis-free survival after stereotactic ablative radiation in oligometastatic prostate cancer","volume":"9","author":"Sutera","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.euo.2025.04.002_b0105","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12885-022-09523-2","article-title":"Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial","volume":"22","author":"Janssen","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2025.04.002_b0110","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2024.01.021","article-title":"Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): primary endpoint results from a phase 2 clinical trial","volume":"85","author":"Nikitas","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.002_b0115","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.04.002_b0120","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.002_b0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13014-023-02302-8","article-title":"Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer","volume":"18","author":"Mohan","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euo.2025.04.002_b0130","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2023.04.025","article-title":"Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer","volume":"84","author":"Sutera","year":"2023","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:33:51Z","timestamp":1766511231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2588931125000902"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncological Outcomes in Patients with Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography\u2013detected Oligometastatic Prostate Cancer Treated with Metastasis-directed Radiotherapy as the Single Treatment Modality","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}